California Liver Research Institute

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)11 trials
• Liver cirrhosis9 trials
• Primary biliary cholangitis6 trials
• Liver and biliary tract cancer5 trials
• High blood pressure4 trials
• Hepatitis B2 trials
• Obesity2 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• Peripheral artery disease1 trial
• Stroke1 trial
• and 1 more

Phase

• Phase 211 trials
• Phase 37 trials
• Phase 12 trials
• Phase 2/31 trial

Status

• Active, not recruiting8 trials
• Completed8 trials
• Terminated6 trials
• Recruiting4 trials
• Not yet recruiting1 trial

Lead sponsor

• Boehringer Ingelheim5 trials
• Gilead Sciences4 trials
• Target PharmaSolutions, Inc.4 trials
• Regeneron Pharmaceuticals3 trials
• Eisai Inc.2 trials
• and 9 more

Running trials

• Not yet recruiting

  ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

  NCT07527910· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

  NCT06096779· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  NCT05519475· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

  NCT05064553· Exact Sciences Corporation· Source

• Active, not recruiting

  Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

  NCT03301506· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study of E7386 in Participants With Selected Advanced Neoplasms

  NCT03264664· Phase 1· Eisai Inc.· Source

• Active, not recruiting

  A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

  NCT02954094· Target PharmaSolutions, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)4 recruiting
• Liver cirrhosis1 recruiting
• Obesity1 recruiting
• Primary biliary cholangitis1 recruiting

Closed trials

• Terminated

  A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

  NCT06082843· Phase 2· Boehringer Ingelheim· Source

• Completed

  Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

  NCT06060665· Phase 3· Gilead Sciences· Source

• Terminated

  A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

  NCT07052682· Phase 1· Takeda· Source

• Completed

  Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

  NCT05525520· Phase 2· Escient Pharmaceuticals, Inc· Source

• Terminated

  A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05282121· Phase 2· Boehringer Ingelheim· Source

• Terminated

  A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05161481· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

  NCT04763408· Eisai Inc.· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Galectin Therapeutics Inc.· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Terminated

  An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

  NCT03692897· Target PharmaSolutions, Inc.· Source

• Completed

  A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

  NCT02932449· Target PharmaSolutions, Inc.· Source

• Completed

  A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

  NCT02815891· Target PharmaSolutions, Inc.· Source